Clinical Trial
Study Details
All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
Outcomes
The number of patients who underwent a PYP SPECT scan diagnostic of ATTR-CM will be assessed and reported
The number of patients who died from all-cause mortality will be tabulated and reported
The number of patients admitted to the hospital with a primary diagnosis of heart failure will be tabulated and reported
The number of patients admitted to the hospital with any diagnosis will be tabulated and reported
Study Overview
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.
Contacts and Locations
Montefiore Health System
Bronx, NY 10467
United States
Participation Criteria
Inclusion Criteria:
* All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023
Exclusion Criteria:
* Did not have a transthoracic echocardiogram in our medical records
All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023 who had a transthoracic echocardiogram in our medical records.